Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

BACKGROUND: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of dep...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Gan, Hui K, Reardon, David A, Lassman, Andrew B, Merrell, Ryan, van den Bent, Martin, Butowski, Nicholas, Lwin, Zarnie, Wheeler, Helen, Fichtel, Lisa, Scott, Andrew M, Gomez, Erica J, Fischer, JuDee, Mandich, Helen, Xiong, Hao, Lee, Ho-Jin, Munasinghe, Wijith P, Roberts-Rapp, Lisa A, Ansell, Peter J, Holen, Kyle D, Kumthekar, Priya
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961429/
https://ncbi.nlm.nih.gov/pubmed/29077941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox202
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky